We are developing a groundbreaking Transfemoral Mitral Chordal Repair system, addressing the significant challenge of Mitral Regurgitation.

While the current standard of care is open heart surgery, the company has developed an innovative minimally invasive leaflet-preserving device, that avoids puncturing the leaflet and allows for future interventions if needed, while reducing the regurgitation.